Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. It’s been a minute since I’ve wished you a good morning.
Morning! We’ve got some big news on Revolution Medicines’ pancreatic cancer treatment.
But don’t miss GSK’s move to push an ovarian cancer ADC into five Phase 3 trials after striking early data. And Spyre Therapeutics released some competitive ulcerative colitis results.  Continue to STAT+ to read the full story...
STAT News published a clinical update in Research Highlights on 13 Apr 2026.
The item focuses on STAT+: GSK advancing ovarian cancer drug mo-rez.
Review the original article for the full source wording and details.